· Immunoscore® Colon is strongly prognostic in the N0147 600 patient cohorts
· Using pre-specified cut off in a retro-prospective design, these results provide a significant level of evidence
· Immunoscore® Colon is clinically useful and reliable to identify high risk stage III colon cancer patients
Marseille, France, June 3, 2017 – HalioDx SAS, an immuno-oncology diagnostic company, announced the presentation of data on Immunoscore® Colon providing a retro-prospective validation on a US clinical cohort (FOLFOX-treated resected stage III colon cancer patients) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
In the study presented by Dr Sinicrope, Mayo Clinic, Rochester, MN (poster abstract #3579), the prognostic value of individual immune markers and of the standardized Immunoscore® Colon test was evaluated in stage III colon cancer (CC) patients treated with adjuvant FOLFOX. Six hundred (600) resected tumors of stage III CC patients from the FOLFOX arm of the prospective NCCTG N0147 clinical trial were analysed retrospectively for 3 individual immune markers (CD3, CD8 and CD20), and for Immunoscore® (IS 0 to IS 4). In this population, the study has demonstrated that risk classification based on immune markers density analysis in core tumor and invasive margin provides valuable prognostic information.
Immunoscore® Colon, based on a standardized method and validated pre-specified cutoffs, showed a strong association with relapse in this cohort. Immunoscore Low (IS 0-1) was associated with worse DFS (HR=0.64, CI, 0.45-0.92, p=0.015); therefore, Immunoscore® Colon is clinically useful and reliable to identify high risk patients.
These results provide an additional clinical level of evidence and validate the strong prognostic value of the CE-IVD Immunoscore® Colon assay in a retro-prospective US clinical trial cohort.
Vincent FERT, CEO of HalioDx comments:
“The N0147 study results provide a second landmark achievement for Immunoscore® Colon. Combining SITC results communicated at ASCO last year and now the NO147 study results we reach a significant level of evidence for Immunoscore® Colon. We have several other large retro-prospective studies on-going that will further reinforce Immunoscore® Colon medical value to support the wide dissemination of this assay”
Poster Session: Gastrointestinal (Colorectal cancer)
Poster Board #202
Session Time/Location: Saturday, June 3, 2017: 8:00-11:30 AM CDT, Hall A
Presenter: Frank A. Sinicrope, MD, Mayo Clinic, Rochester, MN
 Disease Free Survival.